CO4700526A1 - Compuestos novedosos, la preparacion y el uso de estos - Google Patents

Compuestos novedosos, la preparacion y el uso de estos

Info

Publication number
CO4700526A1
CO4700526A1 CO96029749A CO96029749A CO4700526A1 CO 4700526 A1 CO4700526 A1 CO 4700526A1 CO 96029749 A CO96029749 A CO 96029749A CO 96029749 A CO96029749 A CO 96029749A CO 4700526 A1 CO4700526 A1 CO 4700526A1
Authority
CO
Colombia
Prior art keywords
residue
tert
norleucil
valyl
methyl
Prior art date
Application number
CO96029749A
Other languages
English (en)
Inventor
Andreas Haupt
Franz Emling
Cynthia A Romerdahl
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of CO4700526A1 publication Critical patent/CO4700526A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Péptidos novedosos de la fórmula I:R1 R2 N-CHX-CO-A-B-D-E-(F)t-K en donde R1 es metilo, etilo o isopropilo; R2 es hidrógeno, metilo o etileno; R1 -N-R2 juntos pueden ser un anillo de pirrolidina; A es un residuo de valil, isoleucil, leucil, 2-tert-butilglicil, 2-etilglicil-norleucil o norvalil; B es un residuo de N-metil-valil, -leucil, -isoleucil, norvalil, norleucil, 2-tert-butilglicil, -3-tert-butilalamil, o 2-etilglicil; D es un residuo 3,4-de hidroprolil, 4-fluoroprolil, 4,4-difluoroprolil,azetidina-2-carbonil, 3-metilprolil, 4-metilprolil, o 5-metilpropil; E es un residuo propil, homopropil, hidroxipropil o tiazolidina-4-carbonil;F es un residuo de valil, 2-tert-butilglicil-isoleucil, leucil 2-ciclohexilglicil, norleucil, norvalil, neopentilglicil, alanil, ß-alanil o aminoisobutiroil;X es alkilo (preferiblemente C2-5 ), ciclopropil, o ciclopentilo; t es 0 ó 1; yK es alkoxi (Preferiblemente C1-4 ), benxiloxi o una traza amino substituida o no substituida;y las sales de los mismos con ácido tolerados fisiológicamente.
CO96029749A 1995-06-07 1996-06-07 Compuestos novedosos, la preparacion y el uso de estos CO4700526A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides

Publications (1)

Publication Number Publication Date
CO4700526A1 true CO4700526A1 (es) 1998-12-29

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
CO96029751A CO4700527A1 (es) 1995-06-07 1996-06-07 Nuevos peptidos, su preparacion y su uso
CO96029749A CO4700526A1 (es) 1995-06-07 1996-06-07 Compuestos novedosos, la preparacion y el uso de estos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CO96029751A CO4700527A1 (es) 1995-06-07 1996-06-07 Nuevos peptidos, su preparacion y su uso

Country Status (33)

Country Link
US (1) US5831002A (es)
EP (2) EP0832104B1 (es)
JP (2) JP4221062B2 (es)
KR (2) KR100437985B1 (es)
CN (2) CN1182153C (es)
AR (2) AR003136A1 (es)
AT (2) ATE223431T1 (es)
AU (2) AU725170B2 (es)
BG (2) BG102125A (es)
BR (2) BR9609423A (es)
CA (2) CA2219819C (es)
CO (2) CO4700527A1 (es)
CZ (2) CZ293682B6 (es)
DE (2) DE69623992T2 (es)
DK (2) DK0871656T3 (es)
ES (2) ES2186783T3 (es)
HR (2) HRP960257A2 (es)
HU (2) HU228071B1 (es)
IL (2) IL122216A (es)
MX (2) MX9709146A (es)
MY (2) MY119042A (es)
NO (2) NO317670B1 (es)
NZ (2) NZ310444A (es)
PL (2) PL185762B1 (es)
PT (2) PT871656E (es)
RO (2) RO119783B1 (es)
SI (2) SI0832104T1 (es)
SK (1) SK282466B6 (es)
TR (2) TR199701545T1 (es)
TW (2) TW508357B (es)
UA (2) UA46775C2 (es)
WO (2) WO1996040752A1 (es)
ZA (2) ZA964710B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
CN100350036C (zh) 2001-04-27 2007-11-21 宝洁公司 用于控制生物膜的装置和方法
AU2002359792A1 (en) * 2001-12-18 2003-06-30 Proteologics, Inc. Methods and compositions for the inhibition of viral release
WO2003072754A2 (en) * 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2007024574A2 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
WO2007043048A2 (en) * 2005-10-11 2007-04-19 Ramot At Tel Aviv University Ltd. Self-assembled fmoc-ff hydrogels
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
US8143426B2 (en) * 2006-07-24 2012-03-27 Tetralogic Pharmaceuticals Corporation IAP inhibitors
JP5441883B2 (ja) 2007-04-12 2014-03-12 シノファーム タイワン，リミテッド ガランタミンの製造方法
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
SG182724A1 (en) 2010-02-12 2012-08-30 Pharmascience Inc Iap bir domain binding compounds
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CA2821340A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EA201391756A1 (ru) * 2011-05-27 2014-05-30 Амбркс, Инк. Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
DE69230824T2 (de) * 1991-08-09 2000-07-27 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate
JP3523253B2 (ja) * 1992-05-20 2004-04-26 アボット ゲーエムベーハー ウント カンパニー カーゲー ドラスタチン誘導体
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides

Also Published As

Publication number Publication date
ES2188759T3 (es) 2003-07-01
AU725170B2 (en) 2000-10-05
AR003427A1 (es) 1998-08-05
IL122215A (en) 2001-08-26
ZA964710B (en) 1997-12-08
CZ293683B6 (cs) 2004-07-14
NO975711D0 (no) 1997-12-05
DK0871656T3 (da) 2003-01-27
HRP960277A2 (en) 1997-10-31
NO318384B1 (no) 2005-03-14
PL323723A1 (en) 1998-04-14
EP0871656A1 (en) 1998-10-21
KR100437986B1 (ko) 2004-09-18
JPH11504652A (ja) 1999-04-27
TR199701544T1 (xx) 1998-03-21
HU228073B1 (hu) 2012-09-28
AU6124196A (en) 1996-12-30
DE69623992T2 (de) 2003-05-22
SK165397A3 (en) 1998-10-07
CN1187198A (zh) 1998-07-08
DK0832104T3 (da) 2003-01-06
EP0832104B1 (en) 2002-09-04
IL122216A0 (en) 1998-04-05
DE69623472T2 (de) 2003-08-21
KR19990022583A (ko) 1999-03-25
KR19990022582A (ko) 1999-03-25
DE69623992D1 (de) 2002-10-31
AR003136A1 (es) 1998-07-08
ATE224910T1 (de) 2002-10-15
HUP9801910A3 (en) 1999-06-28
HUP9801817A3 (en) 1999-06-28
ZA964711B (en) 1997-12-08
UA46776C2 (uk) 2002-06-17
HRP960257A2 (en) 1998-02-28
CZ376397A3 (cs) 1998-06-17
CN1182153C (zh) 2004-12-29
NO975710D0 (no) 1997-12-05
BG102125A (en) 1998-09-30
CN1187199A (zh) 1998-07-08
NO317670B1 (no) 2004-11-29
NO975710L (no) 1998-02-02
JP3957751B2 (ja) 2007-08-15
NZ310443A (en) 1999-10-28
EP0871656B1 (en) 2002-09-25
CA2219819C (en) 2008-05-20
US5831002A (en) 1998-11-03
JP4221062B2 (ja) 2009-02-12
RO119783B1 (ro) 2005-03-30
CA2219818A1 (en) 1996-12-19
MY119042A (en) 2005-03-31
CN1182154C (zh) 2004-12-29
TW424096B (en) 2001-03-01
MX9709147A (es) 1998-03-31
PT871656E (pt) 2002-12-31
BR9609424A (pt) 2000-03-28
NO975711L (no) 1998-01-30
CA2219818C (en) 2008-05-20
IL122216A (en) 2002-02-10
CA2219819A1 (en) 1996-12-19
HUP9801817A2 (hu) 1998-11-30
RO118953B1 (ro) 2004-01-30
ES2186783T3 (es) 2003-05-16
TR199701545T1 (xx) 1998-04-21
HU228071B1 (hu) 2012-09-28
TW508357B (en) 2002-11-01
CZ293682B6 (cs) 2004-07-14
MX9709146A (es) 1998-03-31
NZ310444A (en) 1999-11-29
AU725164B2 (en) 2000-10-05
SI0871656T1 (en) 2003-08-31
PL185763B1 (pl) 2003-07-31
PL323726A1 (en) 1998-04-14
JPH11504653A (ja) 1999-04-27
SK282466B6 (sk) 2002-02-05
BG102152A (en) 1998-09-30
HUP9801910A2 (hu) 1999-01-28
DE69623472D1 (de) 2002-10-10
KR100437985B1 (ko) 2004-09-18
UA46775C2 (uk) 2002-06-17
ATE223431T1 (de) 2002-09-15
WO1996040752A1 (en) 1996-12-19
CZ376597A3 (cs) 1998-06-17
AU6124296A (en) 1996-12-30
PL185762B1 (pl) 2003-07-31
BR9609423A (pt) 1999-06-29
CO4700527A1 (es) 1998-12-29
IL122215A0 (en) 1998-04-05
MY124487A (en) 2006-06-30
EP0832104A1 (en) 1998-04-01
SI0832104T1 (en) 2003-08-31
WO1996040751A1 (en) 1996-12-19
PT832104E (pt) 2002-12-31

Similar Documents

Publication Publication Date Title
CO4700526A1 (es) Compuestos novedosos, la preparacion y el uso de estos
HUP0100043A2 (hu) Savérzékeny hatóanyagot tartalmazó új gyógyszerforma
TW334418B (en) Stilbene derivatives and pharmaceutical compositions
IL133623A0 (en) Antithrombotic agents
IL133627A0 (en) Antithrombotic agents
ES2195355T3 (es) Formulado farmaceutico que contiene voriconazol.
DK0641343T3 (da) 4-Mercaptoacetylamino-[2]benzazepinon(3)-derivater og anvendelse som enkefalinaseinhibitorer
AR001440A1 (es) Nuevos taxoides, su preparación y composiciones farmacéuticas que los contienen.
BRPI0111639B8 (pt) uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
AR038434A2 (es) Compuesto 14,15-dihidro-16-oxoparahercuamida y compuestos 2-desoxo de parahercuamida y marcfortina
HUP0100669A2 (hu) Szerin proteázokat gátló peptidszármazékok és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
AR024364A1 (es) Una composicion cosmetica para el adelgazamiento a base l-arginina, de un analogo de l-arginina, o de uno de sus derivados, que se administra por viatopica
UY24625A1 (es) Derivados de la 4-hidroxi-piperidina
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
GB2380939B (en) Treatment or prevention of auto-immune diseases
DK0736029T3 (da) Antikonvulsive pseudofructopyranosesulfamater
CO4940448A1 (es) Modificacion a cristal de una sustancia de medicamento
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
HUP0202729A2 (hu) Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények
AR003456A1 (es) Un compuesto analogo de distamicina y sus sales, procedimiento para su preparacion, composicion farmaceutica que lo contiene y usos del mismo.
HUP0105308A2 (hu) Eletriptán-hidrobromid-monohidrát, eljárás az előállítására és a vegyületet tartalmazó gyógyszerkészítmények
DK0452204T3 (da) Hidtil ukendte 3-aminochromanderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
ES2173626T3 (es) Metodos y composiciones para tratar la artritis reumatoide.
ES2156616T3 (es) (r)-5-bromo-n-(1-etil-4-metilhexahidro-1h-1,4-diazepan-6-il)-2-metoxi-6-metilamino-3-piridincarboxamida, procedimiento para su produccion y composicion medicinal que la contiene.
HUP0000882A2 (hu) NMDA (N-metil-D-aszpartát) antagonista hatású indolszármazékok, valamint a vegyületeket tartalmazó gyógyszerkészítmények